Category: Include on Menu
-
Gold Prices Rebound Above $4,300 Ahead of Federal Reserve Rate Decision
Gold prices rose on Wednesday after two consecutive sessions of losses, with investors awaiting the Federal Reserve’s interest rate decision later in the day. At 06:31 GMT, spot gold (XAU/USD) gained 0.8% to $4,326.44 an ounce, while gold futures increased 0.8% to $4,366.50. Silver (XAG/USD) advanced 1.4% to $64.59 an ounce, and platinum (XPT/USD) rose…
-
Oil Prices Fall as Saudi Arabia Offers Additional Crude Shipments Through Oman
Oil prices declined on Wednesday following reports that Saudi Arabia was offering additional crude cargoes to Asian refiners through Oman, easing some concerns about the extent of supply disruptions in the Middle East. At 08:01 GMT, Brent crude futures were down 83 cents, or 0.76%, at $107.92 a barrel. US West Texas Intermediate futures fell…
-
US Stock Futures Rise Ahead of Fed Decision as Oil Prices Ease and AI Developments Draw Attention: Dow Jones, S&P, Nasdaq, Wall Street
US stock futures moved higher on Wednesday as investors awaited the Federal Reserve’s interest rate decision. Oil prices declined following an unexpected increase in US inventories, while developments involving Meta and OpenAI remained in focus. At 07:12 GMT, Dow futures were up 129 points, or 0.3%. S&P 500 futures gained 21 points, or 0.3%, while…
-
Wall Street Pulls Back as Treasury Yields Hit 2007 Highs Ahead of Fed Decision
U.S. stocks retreated on Tuesday as investors turned cautious on the eve of the Federal Reserve’s closely watched policy decision and a surge in Treasury yields rattled the market. All three major indexes finished in the red, with the pullback led by rate-sensitive corners of the market. The yield on the benchmark 10-year Treasury note…
-
Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance
Connect Biopharma reported a statistically significant improvement in lung function in its Phase 2 Seabreeze STAT asthma trial, while a 66% reduction in treatment failures did not reach statistical significance. Key Investor Takeaways Why CNTB Stock Is in Focus Connect Biopharma reported preliminary topline data from its 160-patient Phase 2 Seabreeze STAT Asthma study evaluating…
-
Cheetah Net JoyPak Acquisition Expands Into Consumer and Beauty Products
Cheetah Net agreed to acquire JoyPak Supply for $788,000 in cash, adding consumer, beauty and personal care products as the company continues to diversify beyond logistics and industrial equipment trading. Key Investor Takeaways Why CMCM Stock Is in Focus Cheetah Net has signed a Membership Interest Purchase Agreement to acquire all of JoyPak Supply for…
-
Vera Bradley Q2 Results Show Revenue Growth and Return to Operating Profit
Vera Bradley reported second-quarter fiscal 2027 revenue growth of 1.1%, while stronger direct-channel sales and a tariff refund helped the company swing from an operating loss to a profit. Key Investor Takeaways Why VRA Stock Is in Focus Vera Bradley’s Q2 results showed further improvement in its direct-to-consumer business, helping offset a substantial contraction in…
-
Castle Biosciences TissueCypher Study Shows Improved Risk-Aligned Barrett’s Esophagus Management
A decision modeling study found that TissueCypher-guided care could increase appropriate treatment decisions for Barrett’s esophagus patients, including earlier escalation for non-dysplastic patients who later progress to high-grade dysplasia or cancer. Key Investor Takeaways Why CSTL Stock Is in Focus Castle Biosciences announced a decision modeling study evaluating whether its TissueCypher Barrett’s Esophagus test could…
-
SU Group Exclusive X-Ray Distribution Rights Expand Into Industrial Inspection
SU Group secured exclusive Hong Kong and Macau distribution rights for HDX’s TRACELINE PX3 portable X-ray system, marking its second international distribution agreement of 2026 and extending its product portfolio into industrial inspection applications. Key Investor Takeaways Why SUGP Stock Is in Focus SU Group has secured exclusive distribution rights in Hong Kong and Macau…
-
F5 Agentic AI Detection Expands Bot Defense Against Automated Account Abuse
F5 added agentic AI protections and new device intelligence capabilities to Distributed Cloud Bot Defense, extending its security controls as autonomous AI agents increase interactions with websites, applications and APIs. Key Investor Takeaways Why FFIV Stock Is in Focus F5 has introduced agentic AI detection alongside device intelligence enhancements for its Distributed Cloud Bot Defense…